KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Free Cash Flow (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Free Cash Flow data on record, last reported at $922.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 44.71% year-over-year to $922.0 million; the TTM value through Dec 2025 reached $4.5 billion, up 5.43%, while the annual FY2025 figure was $4.1 billion, 4.41% down from the prior year.
  • Free Cash Flow reached $922.0 million in Q4 2025 per REGN's latest filing, down from $1.6 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.0 billion in Q4 2022 and bottomed at -$133.2 million in Q3 2021.
  • Average Free Cash Flow over 5 years is $994.8 million, with a median of $1.0 billion recorded in 2024.
  • Peak YoY movement for Free Cash Flow: plummeted 115.0% in 2021, then skyrocketed 572.15% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$133.2 million in 2021, then soared by 1636.11% to $2.0 billion in 2022, then crashed by 46.74% to $1.1 billion in 2023, then soared by 53.02% to $1.7 billion in 2024, then crashed by 44.71% to $922.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $922.0 million in Q4 2025, $1.6 billion in Q3 2025, and $1.1 billion in Q2 2025.